DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claims and Previous Objections/Rejections Status
Claims 1,26,27,29,30,32-34,36 and 43 are pending in the application. Claims 2-25,28,31,35 and 37-42 are cancelled and claim 43 is added in the amendment filed 5/22/26.
Any objections and/or rejections from previous office actions that have not been reiterated in this office action are obviated.
New Grounds of Rejection
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claim(s) 32-34 and 43 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cortes-
Salva et al. (Molecules 2018, 23, 2850, p1-10) in view of Mann et al. (US 2008/0138282A1) and in further view of Toyokuni et al. (WO03/089013).
Cortes-Salva et al. (Molecules 2018, 23, 2850, p1-10) discloses the COX-2 inhibitor compound
PNG
media_image1.png
120
212
media_image1.png
Greyscale
(p6, scheme 1).
The
PNG
media_image2.png
48
92
media_image2.png
Greyscale
encompasses the
PNG
media_image3.png
62
88
media_image3.png
Greyscale
moiety of the of the instant claims when
R1 is hydrogen.
The
PNG
media_image4.png
68
44
media_image4.png
Greyscale
encompasses the
PNG
media_image5.png
80
46
media_image5.png
Greyscale
moiety of the of the instant claims.
The
PNG
media_image6.png
44
74
media_image6.png
Greyscale
encompasses the
PNG
media_image7.png
48
80
media_image7.png
Greyscale
moiety of the instant claims .
Cortes-Salva et al. does not disclose the Me moiety of the
PNG
media_image8.png
26
52
media_image8.png
Greyscale
is 11CH3.
Mann et al. (US 2008/0138282A1) discloses COX-2 compounds
PNG
media_image9.png
66
156
media_image9.png
Greyscale
wherein A is 3- to 7-membered heterocycle, etc.; R1 is 11C-labeled C1-C6- alkyl group, etc.; R2 is -aryl, etc.; and R3 is -halo, such as -F, -Cl, etc. (p2, [0011-0015]; p4, [0046]).
The 3- to 7-membered heterocycle comprises pyrimidinyl, etc. that may be substituted with one or more halo groups, such as -F, -Cl, etc. (p4, [0046],[0048]).
The 11C-labeled C1-C6- alkyl group comprises 11CH3, etc. (p2, [0037]) and encompasses the 11CH3
of the instant claims.
It would have been obvious to one of ordinary skill in the art before the effective filing date of
the claimed invention to substitute the Me of the
PNG
media_image8.png
26
52
media_image8.png
Greyscale
of Cortes-Salva et al. for 11CH3 as Mann et al. teaches of the advantage of
PNG
media_image10.png
50
70
media_image10.png
Greyscale
from a finite list of radiolabeled groups for the advantage of in vivo monitoring of COX-2 via PET (p1, [0009]) via monitor the progress or regression of an inflammatory disease (p1, [0009]).
With regards to the instant claim 33, Cortes-Salva et al. does not disclose the substitution of the -F substituted on the pyrimidinyl moiety
PNG
media_image5.png
80
46
media_image5.png
Greyscale
for -Cl.
Cortes-Salva et al. further discloses
PNG
media_image11.png
90
196
media_image11.png
Greyscale
(Scheme 1).
Mann et al. further discloses that the 3- to 7-membered heterocycle comprises pyrimidinyl, etc. that may be substituted with one or more halo groups, such as -F, -Cl, etc. (p4, [0046],[0048]).
It would have been obvious to one of ordinary skill in the art before the effective filing date of
the claimed invention to substitute the -F substituted on the pyrimidinyl moiety
PNG
media_image5.png
80
46
media_image5.png
Greyscale
of Cortes-Salva et al. with a -Cl as Cortes-Salva et al. discloses -Cl substitution on the pyrimidinyl moiety and Mann et al. teaches that the halo substituents, such as -F and -Cl are analogously substituted on the 3- to 7-
membered heterocycle group.
With regards to the instant claim 34, Cortes-Salva et al. does not disclose the substitution of the -F substituted on the pyrimidinyl moiety
PNG
media_image5.png
80
46
media_image5.png
Greyscale
for -CF3.
Toyokuni et al. (WO03/089013) discloses the COX-2 inhibitor imaging probes
PNG
media_image12.png
200
208
media_image12.png
Greyscale
(abstract; p3, lines 4+; p5, lines 25+).
The A moiety comprises a 6-membered ring selected from heteroaryl, such as pyrimidinyl (p3, lines 4+; p6, lines 3-4; p8, lines 26+).
The R1 moiety comprises a methylsulfone (p3, line 12; p6, line 5).
The R2 moiety comprises a heteroaryl group (p3, lines 13-14; p6, lines 6-7).
The R3 moiety comprises a linear or branched alkyl halide, such as trifluoromethyl or a radioactive isotope, such as 18F (p3, lines 15-16; p4, line 28; p6, line 8; p11, lines 24+).
The R4 comprises hydrogen (p3, line 17; p6, line 9).
It would have been obvious to one of ordinary skill in the art before the effective filing date of
the claimed invention to substitute the -F substituted on the pyrimidinyl moiety
PNG
media_image5.png
80
46
media_image5.png
Greyscale
of Cortes-Salva et al. with a -CF3 as Toyokuni et al. teaches that a halo substituent is analogously substituted for an alkyl halide, such as trifluoromethyl on the 6-membered heterocycle group.
Claim(s) 1,26 and 29 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cortes-Salva et al. (Molecules 2018, 23, 2850, p1-10).
Cortes-Salva et al. (Molecules 2018, 23, 2850, p1-10) discloses the COX-2 inhibitor compound
PNG
media_image1.png
120
212
media_image1.png
Greyscale
(p6, scheme 1).
Cortes-Salva et al. does not explicitly disclose the compound
PNG
media_image13.png
122
232
media_image13.png
Greyscale
of the instant claims comprising a benzylamine moiety.
Cortes-Salva et al. further discloses
PNG
media_image14.png
108
204
media_image14.png
Greyscale
wherein R2 comprises 2-Thi or Ph (Table 1).
It would have been obvious to one of ordinary skill in the art before the effective filing date of
the claimed invention to substitute the thiophene moiety for a phenyl moiety as Cortes-Salva et al. teaches of the analogous examination of R2 phenyl and thiophene substituents, from a finite list of substituents, for the advantage of imaging COX-2 via PET (p16, 4. Conclusions).
Cortes-Salva et al. does not explicitly disclose R1 is 18F.
Cortes-Salva et al. further discloses that the compounds are amenable for labeling with fluorine-18 (p4, 2.1. Target Inhibitor Selection for Radioligand Development).
It would have been obvious to one of ordinary skill in the art before the effective filing date of
the claimed invention to substitute the -F substituted on the pyrimidinyl moiety
PNG
media_image4.png
68
44
media_image4.png
Greyscale
of Cortes-Salva et al. with 18F as Cortes-Salva et al. teaches that the COX-2 compounds are amenable for labeling with fluorine-18 for the advantage of imaging COX-2 via PET.
Cortes-Salva et al. does not explicitly disclose the compound
PNG
media_image15.png
128
230
media_image15.png
Greyscale
of the instant claims wherein the benzylamine moiety is bound at the 2-position of the pyrimidinyl moiety.
Cortes-Salva et al. further discloses the compound
PNG
media_image16.png
104
238
media_image16.png
Greyscale
wherein the benzylamine moiety is bound at the 2-position of the pyrimidinyl moiety (Chart 1).
It would have been obvious to one of ordinary skill in the art before the effective filing date of
the claimed invention to bind the benzylamine moiety at the 2-position of the pyrimidinyl moiety, as taught by Cortes-Salva et al. for the examination of various COX-2 compounds for PET imaging of COX-2.
Claim(s) 1,27 and 30 is/are rejected under 35 U.S.C. 103 as being unpatentable over Cortes-Salva et al. (Molecules 2018, 23, 2850, p1-10) in view of Mann et al. (US 2008/0138282A1).
Cortes-Salva et al. (Molecules 2018, 23, 2850, p1-10) discloses the COX-2 inhibitor compounds
PNG
media_image1.png
120
212
media_image1.png
Greyscale
or the compound
PNG
media_image16.png
104
238
media_image16.png
Greyscale
wherein the benzylamine moiety is bound at the 2-position of the pyrimidinyl moiety (Chart 1;
(p6, scheme 1) as well as that stated above.
Cortes-Salva et al. does not explicitly disclose the compounds
PNG
media_image17.png
124
218
media_image17.png
Greyscale
or
PNG
media_image18.png
122
226
media_image18.png
Greyscale
of the instant claims.
Mann et al. (US 2008/0138282A1) discloses COX-2 compounds
PNG
media_image9.png
66
156
media_image9.png
Greyscale
wherein heterocycles comprise a thiazolyl or thiophene, etc. as well as that stated above.
It would have been obvious to one of ordinary skill in the art before the effective filing date of
the claimed invention to substitute the thiophene moiety for a thiazolyl moiety for the examination of COX-2 compounds for PET imaging of COX-2 and monitoring the progress or regression of an inflammatory disease.
It would have been obvious to one of ordinary skill in the art before the effective filing date of
the claimed invention to bind a thiazolyl moiety at the 2-position of the pyrimidinyl moiety, as taught by
Cortes-Salva et al. of for the examination of various COX-2 compounds for PET imaging of COX-2.
Claim(s) 1 and 36 is/are rejected under 35 U.S.C. 103 as being unpatentable over Mann et al. (US 2008/0138282A1).
Mann et al. (US 2008/0138282A1) discloses COX-2 compounds
PNG
media_image9.png
66
156
media_image9.png
Greyscale
wherein A is 3- to 7-membered heterocycle, etc.; R1 is 18F-labeled C1-C6- alkyl group, etc.; R2 is -aryl, etc.; and R3 is -CF3, etc. (p2, [0011-0015]; p4, [0046]).
The 3- to 7-membered heterocycle comprises isoxazoyl, etc. (p4, [0046],[0048]).
The 18F-labeled C1-C6-alkyl group comprises -CH2CH218F, etc. (p2, [0037]).
The aryl comprises phenyl, etc. (p3, [0042]).
Mann et al. does not explicitly disclose the
PNG
media_image19.png
132
186
media_image19.png
Greyscale
compound of the instant claims.
Mann et al. further discloses the compound
PNG
media_image20.png
154
192
media_image20.png
Greyscale
.
It would have been obvious to one of ordinary skill in the art before the effective filing date of
the claimed invention to substitute the -CH218F moiety for the -CH2CH218F as Mann et al. teaches of the
substitution of -CH218F for -CH2CH218F from a finite list of representative 18F-labeled C1-C6- alkyl groups.
Conclusion
No claims are allowed at this time.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA JEAN PERREIRA whose telephone number is (571)272-1354. The examiner can normally be reached M9-3, T9-3, W9-3, Th9-2, F9-2.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/MELISSA J PERREIRA/Examiner, Art Unit 1618